Article Information
History
- September 26, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Hideaki Kato1,2,
- Kei Miyakawa3,
- Norihisa Ohtake4,5,
- Hirofumi Go6,
- Yutaro Yamaoka3,7,
- Satoshi Yajima8,
- Tomoko Shimada9,
- Atsushi Goto10,
- Hideaki Nakajima2 and
- Akihide Ryo3,*
- 1Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan
- 2Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan
- 3Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan
- 4Bioscience Division, Research and Development Department, Tosoh Corporation, Tokyo Research Center, Kanagawa, Japan
- 5Advanced Medical Research Center, Yokohama City University, Yokohama, Japan
- 6Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan
- 7Life Science Laboratory, Technology and Development Division, Kanto Chemical Co, Inc., Isehara, Japan
- 8Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
- 9Nursing Department, Yokohama City University Hospital, Yokohama, Japan
- 10Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Japan
- ↵*Corresponding author
Akihide Ryo, M.D., Ph.D., Department of Microbiology, Yokohama City University School of Medicine, 3-9, Fukuura, Kanazawa, Yokohama, Japan, 236-0004., E-mail: aryo{at}yokohama-cu.ac.jp
Posted September 26, 2021.
Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
